Xiaolin Liu (Co-founder, Chairman & CEO)
As Chairman and CEO of Biotheus, Xiaolin has over 20 years of experience in antibody discovery and development. Previously, Xiaolin served in R&D roles at Abbott, Bristol-Myers Squibb and Adimab. In 2012, Xiaolin was appointed as Vice President of R&D at Innovent Biologics where he led an R&D team of more than 100 scientists, and created a product development pipeline of more than 20 novel antibody-based assets. As the project leader, he successfully oversaw the discvoery, development and and launch of Tyvyt (sintilimab) on the Chinese market.
Joanne Sun (Co-founder, CTO)
Joanne Sun is responsible for Discovery Technologies and CMC Development. Joanne obtained her Ph.D. from Brandeis University in the US and her Post-Doctoratal training at Harvard Medical School. Joanne has more than 20 years of rich experience in quality research and quality control in antibody discovery, development and commercial launching. She has successively served R&D executive positions at Abbott, Bristol-Myers Squibb, Adimab, etc., and participated in the development and quality research of many international best-selling biologics. After returning to China in 2012, she served as Vice President of Innovent Biologics, where she successfully established and led quality, analytical, and translational medicine teams, and made significant contributions to the establishment of their quality system.
Jonathan Hu (CMO)
Jonathan is responsible for clinical research and development. He has more than 20 years of experience in clinical development in oncology, diabetes, respiratory, infectious, autoimmune, cardiovascular, hematological and ophthalmic diseases. Joanathan has previously served at Pfizer and Boehringer Ingelheim, and led many global multi-center clinical trials. He has also served as SVP of clinical development at Innovent Biologics, Vice Executive President and CMO of BetaPharma.
Jun Bao (CBO)
Jun Bao is responsible for Business Development. He obtained his Ph.D. from the University of Kansas, his Postdocotoral training at Johns Hopkins and MBA from the University of Chicago. Dr. Bao has more than 20 years of comprehensive experience in the production and research, extensive experience in drug research and development, technology transfer, licensing and business development, venture investment, entrepreneurship and corporate finance. He has previously served as President & CEO at IMPACT Therapeutics. He also served as SVP & CBO at Shenogen Pharma, Director of Worldwide BD & Head of China BD at GSK，Director of Corporate Development and Financial Planning at Onyx. Moreover, in Seattle, he worked at ICOS Corporation and Cell Therapeutics as a business development executive with progressive responsibilities.
Chat Kwan (SVP & General Manager)
Chat is responsible for the construction and daily operations of Biotheus' new manufacturing facility in Nantong. Chat is an international expert in the design and construction of pharmaceutical manufacturing facilities with more than 30 years’ experience in the field. In China alone, he oversaw the construction of 3 biologics production plants in line with international GMP standards. Chat has previously served as the Vice President of Engineering at CStone Pharmaceuticals, responsible for the design and construction of 73,000 sq.m. facility, including manufacturing and R&D centers that comply with international GMP standards. He also served as the Head of Engineering at Pfizer and completed Pfizer's Hangzhou production facility, Vice President Engineering at Innovent Biologics, responsible for the construction of Innovent Biologics' Suzhou plant, Head of Engineering and Operations at Gilead in the US, and served as Head of a GMP project of Roche, responsible for construction and modification of clean rooms and office buildings in Puerto Rico, France, Mexico and South Korea.
Andy Tsun (Co-founder, SVP)
Andy is responsible for Discovery Biology at Biotheus. He obtained his D. Phil. (Ph. D.) from the University of Oxford, and worked as a Postdocotoral Research Scientist/Associate Professor at Institut Pasteur of Shanghai before moving into industry. Andy was previously the Director of Functional Biology at Innovent Biologics, where he was responsible for target selection and lead molecule selection/characterization. During this period, he participated and led the discovery and development of sintilimab until IND filing. Andy also led the discovery and development of multiple therapeutic antibodies to other targets such as OX40, CD47, and LAG-3.
Yingda Xu (VP)
Responsible for quality analysis. Doctor of Michigan State University, USA, Postdoctoral of University of Texas Southwestern Medical Center. Yingda has published more than 20 SCI papers, and presented reports at international conferences such as PEGS and AET several times. As senior researcher in Bristol-Myers Squibb Company (BMS), Yingda was responsible for analysis and development of Orencia Post Marketing Commitment for the FDA. He successfully developed a tryptic peptide mapping method for the quantification of Orencia oxidative deamination products, and the application of this method in the batch release quality control environment was quickly verified. In 2008, he served as the R&D executive of Adimab company and established what is now known as the world's first-class antibody discovery platform by yeast display technology.
Jinbo Wang (VP)
Jinbo is the Vice President of Finance at Biotheus. He holds an MBA from The University of Quebec. He previously served as Vice President of Finance at Alphamab, CFO at Sanpower Biomedical, Vice President of Finance at Innovent Biologics, and Vice President of Finance at Hisun Pfizer. Jinbo has more than 20 years of experience in financial management, cost control, financing, taxation, IPO filing, etc. Jinbo helped Hisun Pfizer to establish its financial accounting and control system. During his work at Innovent Biologics, he led the C and D rounds of financing. At Alphamab, he played a large role in the structural reorganization listing on the Hong Kong Stock Exchange.
Roland Meisel (VP)
Roland is responsible for Business Development for ex-China. He has a Ph. D. and trained as a postdoctoral scientist in organic chemistry from the University of Rostock. Roland previously served as the Senior Director of Business Development at Celonic AG, Head of SPDC at NextPharma, Belgium, Manager of Contract Manufacturing at Miltenyi Biotec GmbH, and Project Manager for medical device development with PlasmaSelect.